Delayed Diagnosis of Congenital Myasthenic Syndromes Erroneously Interpreted as Mitochondrial Myopathies

Author:

Muñoz-García Mariana I.1,Guerrero-Molina María Paz1,de Fuenmayor-Fernández de la Hoz Carlos Pablo1,Bermejo-Guerrero Laura1ORCID,Arteche-López Ana2ORCID,Hernández-Laín Aurelio3,Martín Miguel A.245ORCID,Domínguez-González Cristina145ORCID

Affiliation:

1. Neuromuscular Unit, Neurology Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain

2. Genetics Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain

3. Neuropathology Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain

4. Spanish Network for Biomedical Research in Rare Diseases (CIBERER), 28041 Madrid, Spain

5. Mitochondrial and Neuromuscular Diseases Research Group, 12 de Octubre, Hospital Research Institute (imas12), 28041 Madrid, Spain

Abstract

Background: Congenital myasthenic syndromes (CMSs) and primary mitochondrial myopathies (PMMs) can present with ptosis, external ophthalmoplegia, and limb weakness. Methods: Our method involved the description of three cases of CMS that were initially characterized as probable PMM. Results: All patients were male and presented with ptosis and/or external ophthalmoplegia at birth, with proximal muscle weakness and fatigue on physical exertion. After normal repetitive nerve stimulation (RNS) studies performed on facial muscles, a muscle biopsy (at a median age of 9) was performed to rule out congenital myopathies. In all three cases, the biopsy findings (COX-negative fibers or respiratory chain defects) pointed to PMM. They were referred to our neuromuscular unit in adulthood to establish a genetic diagnosis. However, at this time, fatigability was evident in the physical exams and RNS in the spinal accessory nerve showed a decremental response in all cases. Targeted genetic studies revealed pathogenic variants in the MUSK, DOK7, and RAPSN genes. The median diagnostic delay was 29 years. Treatment resulted in functional improvement in all cases. Conclusions: Early identification of CMS is essential as medical treatment can provide clear benefits. Its diagnosis can be challenging due to phenotypic overlap with other debilitating disorders. Thus, a high index of suspicion is necessary to guide the diagnostic strategy.

Funder

Instituto de Salud Carlos III

Ministerio de Ciencia e Innovación

European Regional Development Fund “A way to make Europe”

Publisher

MDPI AG

Subject

General Medicine

Reference26 articles.

1. Molecular characterization of congenital myasthenic syndromes in Spain;Benito;Neuromuscul. Disord.,2017

2. How common is childhood myasthenia? The UK incidence and prevalence of autoimmune and congenital myasthenia;Parr;Arch. Dis. Child.,2014

3. Guptill, J.T., and Sanders, D.B. (2021). Bradley and Daroff’s Neurology in Clinical Practice, Elsevier.

4. Congenital myasthenic syndromes;Finsterer;Orphanet J. Rare Dis.,2019

5. Congenital myasthenic syndromes: Pathogenesis, diagnosis, and treatment;Engel;Lancet Neurol.,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3